Lewis y/b Hapten Antikörper

Produktnummer ABIN5564290

Der Maus Monoklonal anti-Lewis y/b Hapten Antikörper (Klon SC104) (ABIN5564290) detektiert spezifisch Lewis y/b Hapten in ELISA, FACS, Func, ICC und IHC. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Lewis y/b Hapten Antikörper (ABIN5564290)

Target: Lewis y/b Hapten

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Applikation: ELISA, Flow Cytometry (FACS), Functional Studies (Func), Immunocytochemistry (ICC), Immunohistochemistry (IHC)

Klon: SC104

Produktdetails

Spezifität: Recognizes human sialyltetraosylceramide. Does not bind to blood lympocytes, granulocytes, bone marrow progenitor cells, GM1, GD1a, GT1b or sialyl LewisX antigens.

Kreuzreaktivität: Human

Reinheit: >95 % (SDS-PAGE)

Endotoxin-Niveau: <0.001EU/μg purified protein (LAL test, Lonza).

Immunogen: Tissue cultured colorectal tumor cell lines (C170, C146, Colo205 and JW).

Isotyp: IgG1

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: In PBS.

Konservierungsmittel: Without preservative

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Haltbarkeit: 12 months

Antigendetails

Target: Lewis y/b Hapten

Andere Bezeichnung: Lewisy/b hapten

Hintergrund: Membrane glycolipids represent an unexplored source of tumor-associated antigens. Many of these are overexpressed and altered in tumors compared to normal tissue. Research into aberrant glycosylation and over-expression of glycolipids on the surface of the majority of cancers, coupled with a knowledge of glycolipids as functional molecules involved in a number of cellular physiological pathways, has provided a novel area of targets for cancer immunotherapy. Lewis-y/b is a cell surface carbohydrate blood group antigen expressed at very low levels in normal tissue, but often found to be overexpressed on breast, lung, colon and ovarian cancer cells. Clone SC104 recognizes a unique cell surface antigen sialyltetraosylceramide, expressed by 90 % of colorectal tumors at all clinical stages. SC104 targets colorectal cancer-associated glycolipids and induces tumor cell death in vitro independently of CDC or ADCC or blockade of known survival signaling pathways. It induces apoptotic cell death and synergizes with chemotherapy in vivo in mice.